MedTrace Logo

Atorvastatin as Adjunctive Therapy in COVID-19

NCT04380402 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2021-03-19

No results posted yet for this study

Summary

Objective: To assess whether adjunctive therapy of COVID-19 infection with atorvastatin reduces the deterioration in hospitalized patients and improves clinical outcome.

Conditions

Interventions

DRUG

Atorvastatin

Atorvastatin 40 mg tablet

Sponsors & Collaborators

  • Mount Auburn Hospital

    lead OTHER

Principal Investigators

  • Lin H Chen, MD · Mount Auburn Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-25
Primary Completion
2021-12-31
Completion
2022-05-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04380402 on ClinicalTrials.gov